You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

Article info

Article menu
XML
Oncolytic and local immunotherapy
Original research
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

Authors

  • Felix Zirngibl Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, GermanyBerlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Sara M Ivasko Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, GermanyBerlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Laura Grunewald Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Anika Klaus Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Silke Schwiebert Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Peter Ruf Trion Research, Martinsried, Germany PubMed articlesGoogle scholar articles
  • Horst Lindhofer Trion Research, Martinsried, Germany PubMed articlesGoogle scholar articles
  • Kathy Astrahantseff Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Lena Andersch Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Johannes H Schulte Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, GermanyPartner Site Berlin CCCC, German Cancer Consortium, Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Holger N Lode Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany PubMed articlesGoogle scholar articles
  • Angelika Eggert Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, GermanyPartner Site Berlin CCCC, German Cancer Consortium, Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Kathleen Anders Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, GermanyPartner Site Berlin CCCC, German Cancer Consortium, Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Patrick Hundsdoerfer Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, GermanyDepartment of Pediatrics, HELIOS Klinikum Berlin-Buch, Berlin, Germany PubMed articlesGoogle scholar articles
  • Annette Künkele Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt–Universität zu Berlin, Berlin, GermanyPartner Site Berlin CCCC, German Cancer Consortium, Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Felix Zirngibl; felix.zirngibl{at}charite.de
View Full Text

Citation

Zirngibl F, Ivasko SM, Grunewald L, et al
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
Journal for ImmunoTherapy of Cancer 2021;9:e002923. doi: 10.1136/jitc-2021-002923

Publication history

  • Accepted June 18, 2021
  • First published July 20, 2021.
Online issue publication 
November 02, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.